Zura Bio Past Earnings Performance
Past criteria checks 0/6
Zura Bio has been growing earnings at an average annual rate of 65.6%, while the Biotechs industry saw earnings growing at 13.6% annually.
Key information
65.6%
Earnings growth rate
93.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -20.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Zura Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -28 | 21 | 20 |
| 31 Mar 24 | 0 | -60 | 21 | 43 |
| 31 Dec 23 | 0 | -69 | 19 | 44 |
| 30 Sep 23 | 0 | -88 | 17 | 55 |
| 30 Jun 23 | 0 | -81 | 11 | 51 |
| 31 Mar 23 | 0 | -41 | 6 | 27 |
| 31 Dec 22 | 0 | -35 | 4 | 26 |
Quality Earnings: 94E is currently unprofitable.
Growing Profit Margin: 94E is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 94E's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 94E's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 94E is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 94E has a negative Return on Equity (-20.24%), as it is currently unprofitable.